Skip to Main Content

Rise and shine, everyone, another busy day is on the way. Although it does seem hard to imagine how things could get any busier than the past week or so, yes? Well, you know what this means — quaffing a few cups of stimulation to help us along. Feel free to join us. After all, a prescription is not required. Meanwhile, here are some items of interest. Hope you have a smashing day and do stay in touch. Leaks and tips are always welcome …

Teva Pharmaceuticals suffered a setback when a US court invalidated four patents on its best-selling Copaxone multiple sclerosis treatment, Bloomberg News reports. The move paves the way to generic competition — possibly as early as February — to a product that generates one-fifth of its sales, although Teva already plans to appeal the decision. The possibility that generics could become available could erase $1.2 billion in Teva revenue this year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!